Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, hospital‑acquired pneumonia, and meningitis in hospitalized patients.

GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: provides bacterial eradication in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: clears resistant uropathogens in complicated cases. - Hospital‑acquired pneumonia: treats pneumonia caused by multidrug‑resistant organisms. - Ventilator‑associated pneumonia: effective against pathogens in ventilated patients. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis. - Severe sepsis and septic shock: rapid bactericidal activity supports hemodynamic recovery.

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Elevated liver enzymes: transient increase in transaminases. - Injection site phlebitis: local irritation at IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with CNS disorders or renal impairment. - Anaphylaxis: acute hypersensitivity requiring immediate intervention. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Severe neutropenia: marked reduction in white blood cells. - Acute renal failure: worsening kidney function. - Life‑threatening allergic reactions: including Stevens‑Johnson syndrome.

Careful assessment and monitoring are essential when using Meropenem. - Renal function assessment: adjust dose in patients with impaired kidney function. - Monitor for seizures: increased risk in patients with pre‑existing CNS disease. - Check for hypersensitivity: discontinue immediately if allergic signs appear. - Use caution in hepatic impairment: monitor liver function tests regularly. - Avoid concomitant use with valproic acid: may reduce antiepileptic efficacy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Valproic acid: may diminish seizure control. - Probenecid: can increase carbapenem plasma concentrations and toxicity. - Loop diuretics: additive risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: potential additive nephrotoxic effect. - Warfarin: may enhance anticoagulant activity, requiring INR monitoring.